Details of the Drug

General Information of Drug (ID: DM4V6RL)

Drug Name
Ritodrine
Synonyms
Prepar; Ritodrina; Ritodrinium; Utopar; Yutopar; RITODRINE HCL; DU-21220; Ritodrina [INN-Spanish]; Ritodrinium [INN-Latin]; Yutopar (TN); Yutopar S.R; Ritodrine (USAN/INN); Ritodrine [USAN:BAN:INN]; P-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; Erythro-p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; 2-(4-Hydroxyphenethylamino)-1-(4-hydroxyphenyl)propanol; 4-[2-[[(1R,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol
Indication
Disease Entry ICD 11 Status REF
Premature labour JB00 Approved [1]
Therapeutic Class
Sympathomimetics
Affected Organisms
Humans and other mammals
ATC Code
G02CA01: Ritodrine
G02CA: Sympathomimetics, labour repressants
G02C: OTHER GYNECOLOGICALS
G02: OTHER GYNECOLOGICALS
G: GENITO URINARY SYSTEM AND SEX HORMONES
G02CA01: Ritodrine
G02CA: Sympathomimetics, labour repressants
G02C: OTHER GYNECOLOGICALS
G02: OTHER GYNECOLOGICALS
G: GENITO URINARY SYSTEM AND SEX HORMONES
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 287.35
Logarithm of the Partition Coefficient (xlogp) 2.3
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 31 mL/min/kg [3]
Elimination
10% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.7 - 2.6 hours [3]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.9656 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.64% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 4.4 L/kg [3]
Chemical Identifiers
Formula
C17H21NO3
IUPAC Name
4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol
Canonical SMILES
C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)O
InChI
InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1
InChIKey
IOVGROKTTNBUGK-SJCJKPOMSA-N
Cross-matching ID
PubChem CID
33572
ChEBI ID
CHEBI:8872
CAS Number
26652-09-5
UNII
I0Q6O6740J
DrugBank ID
DB00867
TTD ID
D00LFB
INTEDE ID
DR1429

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Modulator [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Sulfotransferase 1A1 (SULT1A1)
Main DME 		DEYWLRK ST1A1_HUMAN Substrate [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Premature labour
ICD Disease Classification JB00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Adrenergic receptor beta-2 (ADRB2) DTT ADRB2 4.88E-01 -0.05 -0.12
Adrenergic receptor beta-2 (ADRB2) DTT ADRB2 7.10E-01 0.06 0.09
Sulfotransferase 1A1 (SULT1A1) DME SULT1A1 3.62E-02 -1.87E-01 -4.46E-01
Sulfotransferase 1A1 (SULT1A1) DME SULT1A1 6.72E-01 6.81E-02 1.62E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ritodrine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Moderate Additive hypertensive effects by the combination of Ritodrine and Methylene blue. Acquired methaemoglobinaemia [3A93] [7]
Ivosidenib DM8S6T7 Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Ivosidenib. Acute myeloid leukaemia [2A60] [8]
Midostaurin DMI6E0R Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Midostaurin. Acute myeloid leukaemia [2A60] [8]
Idarubicin DMM0XGL Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Idarubicin. Acute myeloid leukaemia [2A60] [8]
Arn-509 DMT81LZ Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Arn-509. Acute myeloid leukaemia [2A60] [8]
Gilteritinib DMTI0ZO Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Gilteritinib. Acute myeloid leukaemia [2A60] [8]
Oliceridine DM6MDCF Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Oliceridine. Acute pain [MG31] [9]
Ivabradine DM0L594 Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Ivabradine. Angina pectoris [BA40] [8]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Ritodrine and Dronedarone. Angina pectoris [BA40] [8]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Ritodrine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [8]
Cilostazol DMZMSCT Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Cilostazol. Arterial occlusive disease [BD40] [8]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Posaconazole. Aspergillosis [1F20] [8]
Budesonide DMJIBAW Minor Increased risk of hypokalemia by the combination of Ritodrine and Budesonide. Asthma [CA23] [10]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [8]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Ritodrine and Droxidopa. Autonomic nervous system disorder [8D87] [11]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Ofloxacin. Bacterial infection [1A00-1C4Z] [8]
Clarithromycin DM4M1SG Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Clarithromycin. Bacterial infection [1A00-1C4Z] [8]
Gemifloxacin DMHT34O Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [8]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Norfloxacin. Bacterial infection [1A00-1C4Z] [9]
Levofloxacin DMS60RB Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Levofloxacin. Bacterial infection [1A00-1C4Z] [8]
Telithromycin DMZ4P3A Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Telithromycin. Bacterial infection [1A00-1C4Z] [9]
Retigabine DMGNYIH Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Retigabine. Behcet disease [4A62] [9]
Eribulin DM1DX4Q Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Eribulin. Breast cancer [2C60-2C6Y] [8]
Lapatinib DM3BH1Y Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Lapatinib. Breast cancer [2C60-2C6Y] [8]
Bosutinib DMTI8YE Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Bosutinib. Breast cancer [2C60-2C6Y] [8]
Corticotropin DMP9TWZ Minor Increased risk of hypokalemia by the combination of Ritodrine and Corticotropin. Chronic kidney disease [GB61] [10]
PF-04449913 DMSB068 Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [8]
Levomilnacipran DMV26S8 Moderate Increased risk of rapid heart rate by the combination of Ritodrine and Levomilnacipran. Chronic pain [MG30] [12]
Halothane DM80OZ5 Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Halothane. Corneal disease [9A76-9A78] [8]
Sevoflurane DMC9O43 Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Sevoflurane. Corneal disease [9A76-9A78] [8]
Pasireotide DMHM7JS Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Pasireotide. Cushing syndrome [5A70] [8]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Osilodrostat. Cushing syndrome [5A70] [9]
Selegiline DM6034S Moderate Additive hypertensive effects by the combination of Ritodrine and Selegiline. Depression [6A70-6A7Z] [7]
Isocarboxazid DMAF1NB Moderate Additive hypertensive effects by the combination of Ritodrine and Isocarboxazid. Depression [6A70-6A7Z] [7]
Milnacipran DMBFE74 Moderate Increased risk of rapid heart rate by the combination of Ritodrine and Milnacipran. Depression [6A70-6A7Z] [12]
Escitalopram DMFK9HG Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Escitalopram. Depression [6A70-6A7Z] [8]
Desvenlafaxine DMHD4PE Moderate Increased risk of rapid heart rate by the combination of Ritodrine and Desvenlafaxine. Depression [6A70-6A7Z] [12]
Maprotiline DMPWB7T Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Maprotiline. Depression [6A70-6A7Z] [8]
Tetrabenazine DMYWQ0O Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [8]
Deutetrabenazine DMUPFLI Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Deutetrabenazine. Dystonic disorder [8A02] [8]
Ingrezza DMVPLNC Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Ingrezza. Dystonic disorder [8A02] [8]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Solifenacin. Functional bladder disorder [GC50] [8]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [8]
Procarbazine DMIK367 Moderate Additive hypertensive effects by the combination of Ritodrine and Procarbazine. Hodgkin lymphoma [2B30] [7]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Ritodrine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [8]
Lopinavir DMITQS0 Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [9]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [8]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Ritodrine and Crizotinib. Lung cancer [2C25] [8]
Ceritinib DMB920Z Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Ceritinib. Lung cancer [2C25] [8]
Osimertinib DMRJLAT Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Osimertinib. Lung cancer [2C25] [8]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Ritodrine and Selpercatinib. Lung cancer [2C25] [8]
Lumefantrine DM29GAD Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Lumefantrine. Malaria [1F40-1F45] [8]
Hydroxychloroquine DMSIVND Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Hydroxychloroquine. Malaria [1F40-1F45] [8]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Primaquine. Malaria [1F40-1F45] [8]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [8]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Ritodrine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [8]
Vemurafenib DM62UG5 Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Vemurafenib. Melanoma [2C30] [8]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Ritodrine and LGX818. Melanoma [2C30] [8]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Ritodrine and Panobinostat. Multiple myeloma [2A83] [8]
Fingolimod DM5JVAN Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Fingolimod. Multiple sclerosis [8A40] [8]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Ozanimod. Multiple sclerosis [8A40] [13]
Romidepsin DMT5GNL Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Romidepsin. Mycosis fungoides [2B01] [9]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Ritodrine and Nilotinib. Myeloproliferative neoplasm [2A20] [8]
Dasatinib DMJV2EK Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Dasatinib. Myeloproliferative neoplasm [2A20] [8]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Promethazine. Nausea/vomiting [MD90] [8]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Ondansetron. Nausea/vomiting [MD90] [8]
Sibutramine DMFJTDI Moderate Additive hypertensive effects by the combination of Ritodrine and Sibutramine. Obesity [5B80-5B81] [14]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Lofexidine. Opioid use disorder [6C43] [8]
Rucaparib DM9PVX8 Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Rucaparib. Ovarian cancer [2C73] [8]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Buprenorphine. Pain [MG30-MG3Z] [8]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Triclabendazole. Parasitic worm infestation [1F90] [9]
Safinamide DM0YWJC Moderate Additive hypertensive effects by the combination of Ritodrine and Safinamide. Parkinsonism [8A00] [7]
Rasagiline DM3WKQ4 Moderate Additive hypertensive effects by the combination of Ritodrine and Rasagiline. Parkinsonism [8A00] [7]
Pimavanserin DMR7IVC Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Pimavanserin. Parkinsonism [8A00] [8]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Famotidine. Peptic ulcer [DA61] [15]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Ritodrine and Macimorelin. Pituitary gland disorder [5A60-5A61] [16]
Lefamulin DME6G97 Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Lefamulin. Pneumonia [CA40] [8]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Degarelix. Prostate cancer [2C82] [8]
ABIRATERONE DM8V75C Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and ABIRATERONE. Prostate cancer [2C82] [8]
Enzalutamide DMGL19D Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Enzalutamide. Prostate cancer [2C82] [8]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Ritodrine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [8]
Ciclesonide DM2NA4K Minor Increased risk of hypokalemia by the combination of Ritodrine and Ciclesonide. Respiratory system disease [CB40-CB7Z] [10]
Dexamethasone DMMWZET Minor Increased risk of hypokalemia by the combination of Ritodrine and Dexamethasone. Rheumatoid arthritis [FA20] [10]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Quetiapine. Schizophrenia [6A20] [8]
Mesoridazine DM2ZGAN Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Mesoridazine. Schizophrenia [6A20] [8]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Aripiprazole. Schizophrenia [6A20] [15]
Iloperidone DM6AUFY Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Iloperidone. Schizophrenia [6A20] [8]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Paliperidone. Schizophrenia [6A20] [8]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Ritodrine and Amisulpride. Schizophrenia [6A20] [8]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Asenapine. Schizophrenia [6A20] [8]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Ritodrine and Pimozide. Schizophrenia [6A20] [8]
Methylprednisolone DM4BDON Minor Increased risk of hypokalemia by the combination of Ritodrine and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [10]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Ritodrine and LEE011. Solid tumour/cancer [2A00-2F9Z] [17]
Vandetanib DMRICNP Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [8]
Triptorelin DMTK4LS Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [8]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [8]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Pitolisant. Somnolence [MG42] [8]
Telavancin DM58VQX Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [8]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Ritodrine and Lenvatinib. Thyroid cancer [2D10] [8]
Cabozantinib DMIYDT4 Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Cabozantinib. Thyroid cancer [2D10] [8]
Fluticasone DMGCSVF Minor Increased risk of hypokalemia by the combination of Ritodrine and Fluticasone. Vasomotor/allergic rhinitis [CA08] [10]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Ritodrine and Procainamide. Ventricular tachyarrhythmia [BC71] [8]
Propafenone DMPIBJK Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Propafenone. Ventricular tachyarrhythmia [BC71] [8]
Flecainide DMSQDLE Moderate Increased risk of ventricular arrhythmias by the combination of Ritodrine and Flecainide. Ventricular tachyarrhythmia [BC71] [8]
Amiodarone DMUTEX3 Major Increased risk of ventricular arrhythmias by the combination of Ritodrine and Amiodarone. Ventricular tachyarrhythmia [BC71] [8]
⏷ Show the Full List of 105 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7294).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Inhibitory effects of various beverages on ritodrine sulfation by recombinant human sulfotransferase isoforms SULT1A1 and SULT1A3. Pharm Res. 2005 Aug;22(8):1406-10.
7 Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
8 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
9 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
10 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
11 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
12 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
13 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
14 Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
15 Cerner Multum, Inc. "Australian Product Information.".
16 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
17 Canadian Pharmacists Association.